C2N Diagnostics, which offers the PrecivityAD™ blood test as an aid to Alzheimer’s disease diagnosis, launched a new assay for brain health researchers: a high-resolution mass spectrometry-based plasma tau multi-analyte assay (p-tau MAA). The assay uses a small sample of blood and can measure different phosphorylated and nonphosphorylated forms of the tau protein. Abnormal tau and beta-amyloid proteins and several other factors play a vital role in Alzheimer’s-related brain changes. The assay can measure forms of phosphorylation at the tau217 and tau181 sites. This research use only (RUO) assay is expected to allow industry and clinical researchers to further study…
Content Restricted
You must be a Free or Elite member to view this resource.
Log In | Sign up or learn more about membership options.
